Morningstar

Armata Pharmaceuticals Inc ARMP

Stock XASE Rating as of Oct 23, 2026

News

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

PR Newswire Oct 7, 2026, 11:00:00 AM
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

PR Newswire Sep 23, 2026, 11:00:00 AM
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

PR Newswire Sep 21, 2026, 11:00:00 AM
Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment

Global News Select Sep 14, 2026, 1:02:00 PM
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

PR Newswire Sep 14, 2026, 11:00:00 AM
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PR Newswire Sep 10, 2026, 11:00:00 AM
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

PR Newswire Sep 3, 2026, 11:00:00 AM
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

PR Newswire Aug 12, 2026, 8:05:00 PM
Armata Pharmaceuticals Shares Rise on Additional $2.5 Million Government Grant

Global News Select Jun 23, 2026, 11:49:00 AM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.